Table 3.

Intention‐to‐Treat Treatment Effect of Rivaroxaban Versus Warfarin on Type of Death

	Rivaroxaban (n=582)	Warfarin (n=632)	HR (95% CI)	P Value
All‐cause mortality	582 (4.5)	632 (4.9)	0.92 (0.82–1.03)	0.15
Vascular death	375 (2.9)	401 (3.1)	0.94 (0.81–1.08)	0.35
Nonvascular death	148 (1.2)	157 (1.2)	0.94 (0.75–1.18)	0.61
Death unknown cause	59 (0.5)	74 (0.6)	0.80 (0.57–1.12)	0.20
Sudden/unwitnessed death	169 (1.3)	174 (1.4)	0.97 (0.79–1.20)	0.79
CHF/shock cause of death	88 (0.7)	69 (0.5)	1.28 (0.93–1.75)	0.13
Malignancy cause of death	63 (0.5)	55 (0.4)	1.14 (0.80–1.64)	0.46
Intracranial hemorrhage death	27 (0.2)	43 (0.3)	0.63 (0.39–1.02)	0.06

Data are summarized as number of events (event rate per 100 patient‐years of follow‐up), unless otherwise indicated. CHF indicates congestive heart failure; HR, hazard ratio.